Research Analysts Set Expectations for MIST FY2026 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Milestone Pharmaceuticals in a research note issued on Monday, November 16th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.85) for the year, up from their previous forecast of ($0.86). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at ($0.11) EPS and FY2030 earnings at $0.47 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative net margin of 1,860.76% and a negative return on equity of 435.88%. The company had revenue of $2.96 million during the quarter, compared to analyst estimates of $1.00 million.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Piper Sandler dropped their price objective on shares of Milestone Pharmaceuticals to $3.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $5.83.

Get Our Latest Stock Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Stock Up 13.2%

Shares of NASDAQ MIST opened at $0.41 on Wednesday. Milestone Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $3.06. The company’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $1.29. The company has a debt-to-equity ratio of 3.25, a current ratio of 6.27 and a quick ratio of 7.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RVW Wealth LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at approximately $994,000. Virtu Financial LLC increased its holdings in shares of Milestone Pharmaceuticals by 880.3% during the third quarter. Virtu Financial LLC now owns 113,848 shares of the company’s stock valued at $99,000 after acquiring an additional 102,235 shares in the last quarter. Waterloo Capital L.P. acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $40,000. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $68,000. Finally, Valeo Financial Advisors LLC raised its position in shares of Milestone Pharmaceuticals by 12.2% during the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after purchasing an additional 16,000 shares during the period. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

See Also

Earnings History and Estimates for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.